Showing results (1481-1490 of 3,791) with videos related to

Sort By:
Pageof 380
Oncoimmunology|September 20, 2023
CD40 agonism improves anti-tumor T cell priming induced by the combination of radiation therapy plus CTLA4 inhibition and enhances tumor responseMaud Charpentier, Silvia Formenti, Sandra Demaria
Oncoimmunology|July 14, 2023
Accumulation of tissue-resident natural killer cells, innate lymphoid cells, and CD8+ T cells towards the center of human lung tumorsDemi Brownlie, Andreas von Kries, Giampiero Valenzano, et al.
Oncoimmunology|June 19, 2023
Reprogramming the immunosuppressive tumor microenvironment results in successful clearance of tumors resistant to radiation therapy and anti-PD-1/PD-L1Debayan Mukherjee, Erminia Romano, Richard Walshaw, et al.
Oncoimmunology|February 7, 2019
CIITA-related block of HLA class II expression, upregulation of HLA class I, and heterogeneous expression of immune checkpoints in hepatocarcinomas: implications for new therapeutic approachesElise Ramia, Anna Maria Chiaravalli, Farah Bou Nasser Eddine, et al.
Oncoimmunology|February 7, 2019
APOBEC-related mutagenesis and neo-peptide hydrophobicity: implications for response to immunotherapyAmélie Boichard, Timothy V Pham, Huwate Yeerna, et al.
Oncoimmunology|February 7, 2019
PD-1 signaling modulates interferon-γ production by Gamma Delta (γδ) T-Cells in response to leukemiaTimm Hoeres, Elisabeth Holzmann, Manfred Smetak, et al.
Oncoimmunology|February 7, 2019
Interleukin-1 receptor antagonist levels predict favorable outcome after bermekimab, a first-in-class true human interleukin-1α antibody, in a phase III randomized study of advanced colorectal cancerRazelle Kurzrock, Tamas Hickish, Lucjan Wyrwicz, et al.
Oncoimmunology|February 7, 2019
Boosting γδ T cell-mediated antibody-dependent cellular cytotoxicity by PD-1 blockade in follicular lymphomaCédric Rossi, Pauline Gravelle, Emilie Decaup, et al.
Oncoimmunology|February 7, 2019
Exosomes from GM-CSF expressing embryonic stem cells are an effective prophylactic vaccine for cancer preventionKavitha Yaddanapudi, Shuhan Meng, Aaron G Whitt, et al.
Oncoimmunology|September 16, 2020
Dose dependence of treatment-related adverse events for immune checkpoint inhibitor therapies: a model-based meta-analysisBoris Shulgin, Yuri Kosinsky, Andrey Omelchenko, et al.
Pageof 380